TheStreet downgraded InVitae Corp (NASDAQ:NVTA) to Sell in a report released today.
- Updated: September 16, 2016
Just yesterday InVitae Corp (NASDAQ:NVTA) traded 3.81% higher at $8.18. The company’s 50-day moving average is $8.47 and its two hundred day moving average is $8.92. With the last stock close down 8.33% from the two hundred day average, compared to the S&P 500 Index which has fallen -0.01% over the date range. Volume of trade was was up over the average, with 539,119 shares of NVTA changing hands over the typical 118,989 shares..
TheStreet has downgraded InVitae Corp(NASDAQ:NVTA) to Sell in a statement released 9/15/2016.
Recent Performance Chart:
A total of 2 equity analysts have reported on NVTA. Zero rate the stock a strong buy, two analysts rate the stock a buy, two firms rate the company a hold, 0 rate the stock to underperform, and finally 0 brokeragesrate the stock as sell with a 12-month target price of $10.00
InVitae Corp has a 52 week low of $5.66 and a 52 week high of $11.85 . NVTA’s market capitalization is currently $0.0.
More About InVitae Corp (NASDAQ:NVTA)
Invitae Corporation (Invitae) utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions. The Company offers panels for over 120 conditions in hereditary cancer, cardiology, neuromuscular, and pediatric and rare diseases. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. It has developed an offering that enables healthcare professionals to customize a test and receive test results at requisition.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.